Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help improve the speed and success of drug development.

Thermo Fisher Launches OpenAI Partnership at CPHI Frankfurt 2025: Part One

Pharmaceutical Technology® spoke with Peter Freed, head of Global Pharma CTS, Roquette, about a variety of materials-related topics including protein stability, tablet coating, sustainability, and securing the supply chain. 

Sustainability and Stability in Excipients

Feliza Mirasol is the science editor for 

React4Life’s Silvia Scaglione emphasizes how organ-on-chip tech and AI are reshaping drug testing, personalized treatment, and the future of bio/pharma innovation. 

How Organ-on-Chip Tech and AI Are Transforming Drug Development

Pharmaceutical Technology® spoke with Dr. Weite Oldenziel, CEO of Ofichem, before CPHI Frankfurt 2025 to get his perspective on the API market and why it is important to qualify API suppliers.

CPHI Frankfurt 2025: The Current API Market

Articles

Radiopharmaceuticals are allowing for the targeted treatment of cancers, but they do pose challenges. 

Trends Shaping Radiopharmaceutical Development

Pharmaceutical Technology® spoke with Tara Dougal, Event Director for Pharma at Informa Markets about what attendees at CPHI Frankfurt should expect this year.

Tara Dougal Welcomes You to CPHI Frankfurt 2025

Real-world data can be utilized to ensure quality and effectiveness of drug products.

Harnessing Real-World Evidence to Future-Proof Drug Development

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Challenges, Innovations, and Future Outlook of Biologics Formulations

Recent developments show how innovations and treatments for cancer are rapidly advancing.

The Evolving Oncology Landscape

The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data comparable to injection effectiveness.